Compare CHOW & OSRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CHOW | OSRH |
|---|---|---|
| Founded | 2014 | N/A |
| Country | Hong Kong | United States |
| Employees | N/A | 21 |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9M | 11.7M |
| IPO Year | N/A | N/A |
| Metric | CHOW | OSRH |
|---|---|---|
| Price | $0.38 | $0.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 157.3K | ★ 733.3K |
| Earning Date | 01-01-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.38 |
| 52 Week High | $12.05 | $1.79 |
| Indicator | CHOW | OSRH |
|---|---|---|
| Relative Strength Index (RSI) | 36.61 | 58.54 |
| Support Level | N/A | $0.51 |
| Resistance Level | $0.52 | $0.74 |
| Average True Range (ATR) | 0.04 | 0.06 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 34.40 | 69.43 |
ChowChow Cloud International Holdings Ltd is providing one-stop cloud solutions that support companies across the IT industry value chain throughout their entire cloud transformation journey from consulting, deployment and migration to cloud environment building and management. Its business comprises (i) digital transformation consulting services consisting of cloud suitability assessment (ii) professional IT services comprising of capabilities designed to facilitate seamless cloud integration and digital transformation, (iii) AI-powered proactive cloud managed services covering all aspects of day-to-day cloud maintenance and support, and (iv) IT infrastructure solutions covering on-premise private cloud setups and public cloud integrations including infrastructure applications.
OSR Holdings Inc is a healthcare company dedicated to healthcare outcomes and improving the quality of life for people and their families. It builds and develops a robust portfolio of potentially transformative therapies and healthcare solutions. The business of the company includes developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases, and neurovascular intervention medical device and systems distribution in Korea.